This site is intended for healthcare professionals
Drug information

Deximune 100 mg soft capsules

POM
Read time: 35 mins
Last updated: 29 Sep 2020
Published: 30 Jul 2021

4.1 Therapeutic indications

Transplantation Indications

Solid Organ Transplantation

Prevention of graft rejection following solid organ transplantation.

Treatment of transplant rejection in patients previously receiving other immunosuppressive agents.

Bone Marrow Transplantation

Prevention of graft rejection following allogeneic bone marrow and stem cell transplantation.

Prevention or treatment of graft-versus-host disease (GVHD).

Non-Transplantation Indications

Endogenous uveitis

Treatment of sight-threatening intermediate or posterior uveitis of non-infectious aetiology in patients in whom conventional therapy has failed or caused unacceptable side effects.

Treatment of Behçet uveitis with repeated inflammatory attacks involving the retina in patients without neurological manifestations.

Psoriasis

Deximune Capsules are indicated in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate.

Atopic Dermatitis

Deximune Capsules are indicated in patients with severe atopic dermatitis when systemic therapy is required.

Rheumatoid Arthritis

Deximune Capsules are indicated for the treatment of severe, active rheumatoid arthritis.

Nephrotic Syndrome

Steroid-dependent and steroid-resistant nephrotic syndrome due to primary glomerular diseases such as minimal change nephropathy, focal segmental glomerulosclerosis or membranous glomerulonephritis.

Deximune Capsules can be used to induce remissions and for maintenance remissions. It can also be used to maintain steroid-induced remission, allowing withdrawal of steroids.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).